pre-IPO PHARMA

COMPANY OVERVIEW

Antikor Ltd is a newly established company that is exploiting a novel technology platform called OptiLinked-FDCs, to generate revolutionary products to treat solid cancers. They are a multidisciplinary spin-out from Imperial College London UK now based at the Stevenage Bioscience Catalyst. The Company has over 15 years of pioneering experience in the area of small-format, antibody fragment drug conjugates, and has generated product candidates with optimal pharmacokinetics, pharmacodynamics and other encouraging preclinical data.


LOCATION

  • Stevenage, , UK

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.antikor.co.uk/


    CAREER WEBSITE

    https://www.antikor.co.uk/vacancies


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Aug 2, 2019

    Antikor Biopharma and Essex Bio-Technology Forge Strategic Alliance in FDC for Cancer Treatment


    Nov 13, 2017

    Antikor Advances Breakthrough Fragment Drug Conjugate (FDC) Technology Demonstrating Superior Penetration and Tolerability


    Apr 19, 2016

    Breakthrough Achieved by Antikor Biopharma with Fragment-Drug Conjugates


    For More Press Releases


    Google Analytics Alternative